Supplementary Material:

		Hazard ratios			
Ancestry group	p Value	HR _{80/20}	HR _{20/50}	HR _{80/50}	HR _{95/50}
All (n=582,516)	<10 ⁻¹⁶	4.94 [4.58-5.28]	0.45 [0.44-0.47]	2.25 [2.16-2.32]	3.26 [3.09-3.43]
European (n=425,252)	<10 ⁻¹⁶	4.64 [4.28-5.03]	0.47 [0.45-0.49]	2.17 [2.09-2.27]	3.14 [2.95-3.33]
African (n=104,583)	<10 ⁻¹⁶	3.02 [2.6-3.57]	0.59 [0.54-0.63]	1.78 [1.64-1.94]	2.28 [2.04-2.58]
Hispanic (n=45,669)	<10 ⁻¹⁶	3.95 [2.87-5.37]	0.5 [0.43-0.59]	1.99 [1.7-2.32]	2.77 [2.2-3.48]
Asian (n=7015)	<10 ⁻⁴	6.85 [2.84-17.12]	0.37 [0.23-0.58]	2.54 [1.66-3.94]	4.17 [2.14-8.43]

Supplementary Table 1: Association of PHS290 with metastatic prostate cancer. P-values reported are for the overall performance of Cox models using PHS290 as the sole predictor variable. Hazard ratios (HRs) are shown comparing men in various percentiles of genetic risk. HR_{80/20}: highest 20% (≥80th percentile of PHS290, using previously published thresholds for men <70 years old and no diagnosis of cancer) vs. average risk (30-70th percentile). HR_{20/50}: lowest 20% (≤20th percentile) vs. average risk. HR_{80/50}: highest 20% vs. average risk. HR_{95/50}: highest 5% (≥95th percentile) vs. average risk. Numbers in brackets are 95% confidence intervals.

		Hazard ratios			
Ancestry group	p Value	HR _{80/20}	HR _{20/50}	HR _{80/50}	HR _{95/50}
All (n=582,516)	<10 ⁻¹⁶	6.29 [6.14-6.46]	0.4 [0.4-0.41]	2.54 [2.51-2.57]	3.89 [3.83-3.97]
European (n=425,252)	<10 ⁻¹⁶	6.19 [6.01-6.38]	0.41 [0.4-0.41]	2.52 [2.48-2.55]	3.89 [3.81-3.98]
African (n=104,583)	<10 ⁻¹⁶	3.83 [3.61-4.08]	0.52 [0.51-0.54]	2.01 [1.95-2.08]	2.72 [2.6-2.85]
Hispanic (n=45,669)	<10 ⁻¹⁶	4.75 [4.22-5.32]	0.46 [0.43-0.49]	2.18 [2.06-2.31]	3.18 [2.91-3.47]
Asian (n=7015)	<10 ⁻¹⁶	5.52 [3.98-7.56]	0.41 [0.35-0.49]	2.29 [1.96-2.67]	3.56 [2.79-4.57]

Supplementary Table 2: Association of PHS290 with prostate cancer. *P*-values reported are for the overall performance of Cox models using PHS290 as the sole predictor variable. Hazard ratios (HRs) are shown comparing men in various percentiles of genetic risk. HR_{80/20}: highest 20% (≥80th percentile of PHS290, using previously published thresholds for men <70 years old and no diagnosis of cancer) vs. average risk (30-70th percentile). HR_{20/50}: lowest 20% (≤20th percentile) vs. average risk. HR_{80/50}: highest 20% vs. average risk. HR_{95/50}: highest 5% (≥95th percentile) vs. average risk. Numbers in brackets are 95% confidence intervals.

Endpoint	African	African p	Hispanic	Hispanic p	Asian	Asian p	European
Fatal	2.65 [2.37-2.96]	<10 ⁻¹⁶	1.15 [0.9-1.42]	0.24	0.58 [0.17-1.08]	0.15	Ref
Metastatic	3.01 [2.83-3.18]	<10 ⁻¹⁶	1.27 [1.13-1.41]	<10 ⁻⁴	1.02 [0.7-1.37]	0.88	Ref
Prostate Cancer	2.43 [2.38-2.48]	<10 ⁻¹⁶	1.04 [1.0-1.08]	0.05	0.86 [0.76-0.95]	<10 ⁻²	Ref


Supplementary Table 3: Association of ancestry with three prostate cancer clinical endpoints. Hazard ratios (HRs) are shown from Cox-proportional hazards models with ancestry group as the only predictor variable. Numbers in brackets are 95% confidence intervals.

Endpoint	p Value	FH
Fatal	<10 ⁻¹¹	1.84 [1.54-2.17]
Metastatic	<10 ⁻¹⁶	1.67 [1.5-1.83]
Prostate Cancer	<10 ⁻¹⁶	2.06 [2.0-2.12]

Supplementary Table 4: Association of family history with three prostate cancer clinical endpoints. Hazard ratios (HRs) are shown from Cox-proportional hazards models with family history as the only predictor variable. This analysis was limited to the 374,455 participants who provided family history information in baseline survey data. Numbers in brackets are 95% confidence intervals.

		Endpoint		
		Fatal	Metastatic	Prostate Cancer
PHS290	HR _{80/20}	4.05 [3.45-4.75]***	4.11 [3.78-4.49]***	5.66 [5.49-5.84]***
Ancestry	African	1.12 [0.56-2.21]	1.08 [0.71-1.63]	1.13 [0.97-1.32]
	Hispanic	0.87 [0.42-1.68]	1.13 [0.77-1.64]	1.11 [0.98-1.24]
	Asian	0.34 [0.01-2.91]	1.81 [0.49-6.46]	1.0 [0.69-1.48]
Family History	FH	1.68 [1.38-1.99]**	1.52 [1.37-1.69]**	1.91 [1.84-1.97]***
Principal Components	PC1	0.04 [0.0-1.75]	0.02 [0.0-0.16]**	0.07 [0.03-0.15]**
	PC2	0.99 [0.03-19.4]	0.45 [0.06-3.2]	0.5 [0.26-0.96]
	PC3	0.37 [0.01-92.03]	3.88 [0.22-98.93]	0.41 [0.18-1.03]
	PC4	0.1 [0.02-0.39]**	0.07 [0.02-0.18]**	0.84 [0.6-1.17]
	PC5	0.11 [0.01-1.5]	1.0 [0.19-4.98]	3.04 [1.77-5.44]**
	PC6	11.16 [0.42-411.31]	8.15 [0.98-72.75]	2.04 [1.0-4.09]
	PC7	169.35 [0.17-153573.71]	0.58 [0.02-25.5]	1.44 [0.4-4.75]
	PC8	0.01 [0.0-3.17]	0.71 [0.03-18.62]	0.32 [0.12-0.87]
	PC9	0.63 [0.0-175.28]	3.57 [0.17-71.69]	1.64 [0.57-4.77]
	PC10	2.42 [0.04-157.1]	0.16 [0.01-1.81]	0.84 [0.36-2.02]

Supplementary Table 5: Multivariable models combining Ancestry, Family History, Top 10 Population Principal Components, and PHS290 for three prostate cancer clinical endpoints. Cox proportional hazards results for association with age at death from prostate cancer, age at diagnosis of metastatic prostate cancer, and age at diagnosis with prostate cancer. P-values reported are from multivariable models using HARE ancestry group, family history, the top 10 population principal components, and PHS290. For PHS290, effect size was illustrated via the hazard ratio (HR80/20) for the highest 20% vs. lowest 20% of genetic risk. Hazard ratios for ancestry groups were estimated using European as the reference. Hazard ratios for family history were for one or more first-degree relatives diagnosed with prostate cancer. This analysis was limited to the 374,455 participants who provided family history information in baseline survey data. Numbers in brackets are 95% confidence intervals. Significant predictors in the multivariable model are indicated by * (p<0.01), **(10⁻¹⁶<p<0.01) and **** (p<10⁻¹⁶). PHS290 and family history remained significant after addition of the top 10 population principal components, but African ancestry was no longer independently associate with any endpoint.



Supplementary Figure 1. (A) PHS290 score density plot in prostate cancer controls for European, African, Hispanic and Asian ancestry groups. **(B)** PHS290 score density plot in prostate cancer cases for European, African, Hispanic and Asian ancestry groups. These plots do not account for age.